ES2339427T3 - Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer. - Google Patents

Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer. Download PDF

Info

Publication number
ES2339427T3
ES2339427T3 ES02703586T ES02703586T ES2339427T3 ES 2339427 T3 ES2339427 T3 ES 2339427T3 ES 02703586 T ES02703586 T ES 02703586T ES 02703586 T ES02703586 T ES 02703586T ES 2339427 T3 ES2339427 T3 ES 2339427T3
Authority
ES
Spain
Prior art keywords
tau
antibody
tau protein
truncated
human tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02703586T
Other languages
English (en)
Spanish (es)
Inventor
Michal Novak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axon Neuroscience Forschungs- und Entwicklungs GmbH
Axon Neuroscience SE
Original Assignee
Axon Neuroscience Forschungs- und Entwicklungs GmbH
Axon Neuroscience SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Forschungs- und Entwicklungs GmbH, Axon Neuroscience SE filed Critical Axon Neuroscience Forschungs- und Entwicklungs GmbH
Application granted granted Critical
Publication of ES2339427T3 publication Critical patent/ES2339427T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02703586T 2001-02-02 2002-01-29 Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer. Expired - Lifetime ES2339427T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
ATA175/2001 2001-02-02

Publications (1)

Publication Number Publication Date
ES2339427T3 true ES2339427T3 (es) 2010-05-20

Family

ID=3658236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02703586T Expired - Lifetime ES2339427T3 (es) 2001-02-02 2002-01-29 Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer.

Country Status (12)

Country Link
US (2) US7446180B2 (enExample)
EP (1) EP1355949B1 (enExample)
JP (1) JP4163955B2 (enExample)
CN (2) CN100503638C (enExample)
AT (2) AT500379B8 (enExample)
AU (1) AU2002237296A1 (enExample)
CA (1) CA2437453C (enExample)
DE (1) DE60235746D1 (enExample)
DK (1) DK1355949T3 (enExample)
ES (1) ES2339427T3 (enExample)
RU (1) RU2299889C2 (enExample)
WO (1) WO2002062851A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
DE60320258T2 (de) * 2002-07-12 2009-06-25 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
EP2440234A4 (en) * 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
ITRM20100320A1 (it) * 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
CN103339146B (zh) 2010-10-11 2017-09-01 比奥根国际神经科学公司 人抗tau抗体
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
UA115657C2 (uk) 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
MX354662B (es) * 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
EP3792278A3 (en) 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
EP2970452A2 (en) * 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
MY197836A (en) * 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CN109562167A (zh) 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN107686839B (zh) * 2017-09-25 2020-12-04 安徽朵能生物科技有限公司 微管结合蛋白cript、其治疗性突变体及其应用
CN112543648A (zh) 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
AU2020241858B2 (en) 2019-03-18 2024-06-13 Regeneron Pharmaceuticals, Inc. CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation

Also Published As

Publication number Publication date
JP4163955B2 (ja) 2008-10-08
WO2002062851A1 (en) 2002-08-15
DK1355949T3 (da) 2010-05-25
AT500379B8 (de) 2009-08-15
CN100503638C (zh) 2009-06-24
AT500379A2 (de) 2005-12-15
ATE461941T1 (de) 2010-04-15
RU2003126594A (ru) 2005-03-10
US7446180B2 (en) 2008-11-04
CN1492879A (zh) 2004-04-28
AT500379A3 (de) 2009-02-15
US20090123936A1 (en) 2009-05-14
CA2437453C (en) 2013-06-11
US20040082763A1 (en) 2004-04-29
AU2002237296A1 (en) 2002-08-19
EP1355949B1 (en) 2010-03-24
CA2437453A1 (en) 2002-08-15
EP1355949A1 (en) 2003-10-29
CN101307107A (zh) 2008-11-19
RU2299889C2 (ru) 2007-05-27
AT500379B1 (de) 2009-07-15
JP2004532817A (ja) 2004-10-28
DE60235746D1 (de) 2010-05-06
WO2002062851A8 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ES2339427T3 (es) Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer.
Mercken et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes
EP1546734B1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
Paulson et al. Machado‐Joseph disease gene product is a cytoplasmic protein widely expressed in brain
RU2668159C2 (ru) Антитела против тау
Zhang et al. Icariin decreases the expression of APP and BACE-1 and reduces the β-amyloid burden in an APP transgenic mouse model of Alzheimer's disease
ES2230551T3 (es) Procedimientos para ayudar al diagnostico de la enfermedad de alzheimer mediante la medicion del peptido (x- 41)amiloide beta y de la proteina tau.
Iwata et al. Regulatory mechanisms for the axonal localization of tau protein in neurons
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US5733734A (en) Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
US5985581A (en) Use of presenilin-1 for diagnosis of alzheimers disease
JP2019163268A (ja) 病理学的タウタンパク質の免疫学的標的化方法
Sakurai et al. Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing
WO1998004919A9 (en) Use of presenilin-1 for diagnosis of alzheimer's disease
CN113490505A (zh) 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
Goodyear et al. Identification of the hair cell soma-1 antigen, HCS-1, as otoferlin
Takahashi et al. Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits α-synuclein phosphorylation
JPH11504317A (ja) プリオンタンパク質に結合する単離５５〜７５ｋｄａタンパク質
DK2289909T3 (en) The screening method, method of purification of non-diffusing alpha-beta oligomers selective antibodies to said non-diffunderingsdygtige alpha-beta oligomers and a method of producing said antibodies
Verelst et al. A yeast-based model to study the structural properties of the neurodegenerative disease-related protein Tau
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US20170096476A1 (en) Methods and compositions related to amyloid-beta-42 oligomers
Gareus Profilin II: novel functions in membrane trafficking
Duyckaerts et al. Alzheimer’s brain inoculation in Aß-plaque bearing mice: synaptic loss is linked to tau seeding and low microglial activity
DE20320429U1 (de) Monoklonale Antikörpertools für die biokonformatische Analyse